Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NNMT | P40261 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | STAMBP | O95630 | 1/20 | 0.39 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711905 | 1.00 | HPGDS (0.44) | HPGDSNPC1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL843647 | 0.84 | NPC1 (0.57) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL30895185 | 0.84 | NPC1 (0.57) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL10660456 | 0.83 | NPC1 (0.44) | HPGDSNPC1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL12663281 | 0.82 | NPC1 (0.41) | HPGDSNPC1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL21621626 | 0.79 | MAPK1 (0.46) | HPGDSNPC1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL22079499 | 0.77 | NNMT (0.45) | NNMT | |
| SCHEMBL25272200 | 0.75 | HPGDS (0.52) | HPGDSNPC1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL3941119 | 0.75 | NPC1 (0.41) | HPGDSNPC1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL1219793 | 0.74 | KDM4E (0.42) | HPGDSNPC1RAB9AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-13 | — | — | US | claimed |
| US-20220356179-A1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2022-11-10 | — | — | US | claimed |
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2025-02-13 | — | — | US | disclosed |
| US-20240166651-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-05-23 | — | — | US | disclosed |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3724197-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | disclosed |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| CN-1980937-B | Thienopyridone carboxamides and their medical use | ACTIVE BIOTECH AB | 2011-08-10 | — | — | CN | disclosed |
| EP-2341904-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | Fibrogen, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010024908-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010024911-A1 | METHODS FOR INCREASING NEUROGENESIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-7553849-B2 | Compounds | ACTIVE BIOTECH AB (SE) | 2009-06-30 | — | — | US | disclosed |
| EP-1776369-B1 | THIENOPYRIDONE CARBOXAMIDES AND THEIR MEDICAL USE | ACTIVE BIOTECH AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| CN-1980937-A | Thienopyridone carboxamides and their medical use | ACTIVE BIOTECH AB (SE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1776369-A1 | THIENOPYRIDONE CARBOXAMIDES AND THEIR MEDICAL USE | Active Biotech AB (SE) | 2007-04-25 | — | — | EP | disclosed |
| US-20060004038-A1 | Novel compounds | ACTIVE BIOTECH AB (SE) | 2006-01-05 | — | — | US | disclosed |
| WO-2005123744-A1 | THIENOPYRIDONE CARBOXAMIDES AND THEIR MEDICAL USE | ACTIVE BIOTECH AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | MYLK, ROCK1, ROCK2 | HPGDS 599/4885NPC1 4398/4885RAB9A 456/4885 |
| US-20240166651-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK3, JAK1 | HPGDS 526/4885NPC1 4516/4885RAB9A 3268/4885 |
| US-20060004038-A1 | Novel compounds | REL, CLIC4, C5 | HPGDS 2188/4885NPC1 1675/4885RAB9A 1791/4885 |
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | CBR3, C5, CBR1 | HPGDS 4772/4885NPC1 3323/4885RAB9A 585/4885 |
| US-20220356179-A1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | MYLK, ROCK1, ROCK2 | HPGDS 599/4885NPC1 4398/4885RAB9A 456/4885 |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | PMP22, MAG, NEFM | HPGDS 1373/4885NPC1 1125/4885RAB9A 3751/4885 |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | HPGDS, HPGD, PTGS1 | HPGDS 1/4885NPC1 3749/4885RAB9A 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.